Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders' Equity

v3.24.3
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid in Capital
Accumulated Deficit
Treasury Stock
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2022   16,210,776        
Beginning balance at Dec. 31, 2022 $ 63,631 $ 16 $ 109,138 $ 11,753 $ (58,033) $ 757
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock in asset acquisition (in shares)   100,000        
Issuance of common stock in asset acquisition 1,000 $ 1 999      
Repurchases of common shares (in shares)   (69,628)        
Repurchases of common shares (588)       (588)  
Issuance of common stock to convert outstanding convertible notes (in shares)   800,000        
Issuance of common stock to convert outstanding convertible notes 2,400 $ 1 2,399      
Issuance of common stock upon exercise of warrants (in shares)   400,000        
Issuance of common stock upon exercise of warrants 1,200   1,200      
Issuance of common stock upon stock options cashless exercise (in shares)   603,881        
Issuance of warrants with unsecured promissory note 398   398      
Treasury shares repurchased to satisfy tax withholding obligations (5,379)       (5,379)  
Unrealized gain (loss) on marketable securities (2,201)         (2,201)
Stock-based compensation 3,998   3,998      
Net loss (8,031)     (8,031)    
Ending balance (in shares) at Sep. 30, 2023   18,045,029        
Ending balance at Sep. 30, 2023 56,428 $ 18 118,132 3,722 (64,000) (1,444)
Beginning balance (in shares) at Jun. 30, 2023   16,845,029        
Beginning balance at Jun. 30, 2023 59,257 $ 17 113,789 8,863 (64,000) 588
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock to convert outstanding convertible notes (in shares)   800,000        
Issuance of common stock to convert outstanding convertible notes 2,400 $ 1 2,399      
Issuance of common stock upon exercise of warrants (in shares)   400,000        
Issuance of common stock upon exercise of warrants 1,200   1,200      
Unrealized gain (loss) on marketable securities (2,032)         (2,032)
Stock-based compensation 744   744      
Net loss (5,141)     (5,141)    
Ending balance (in shares) at Sep. 30, 2023   18,045,029        
Ending balance at Sep. 30, 2023 $ 56,428 $ 18 118,132 3,722 (64,000) (1,444)
Beginning balance (in shares) at Dec. 31, 2023 18,045,029 18,045,029        
Beginning balance at Dec. 31, 2023 $ 49,383 $ 18 118,694 (5,029) (64,000) (300)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock for cash, net of offering cost (in shares)   1,033,500        
Issuance of common stock for cash, net of offering cost 4,624   4,624      
Unrealized gain (loss) on marketable securities 103         103
Stock-based compensation 3,021   3,021      
Net loss $ (19,005)     (19,005)    
Ending balance (in shares) at Sep. 30, 2024 19,078,529 19,078,529        
Ending balance at Sep. 30, 2024 $ 38,126 $ 18 126,339 (24,034) (64,000) (197)
Beginning balance (in shares) at Jun. 30, 2024   19,078,529        
Beginning balance at Jun. 30, 2024 44,076 $ 18 125,703 (17,447) (64,000) (198)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Unrealized gain (loss) on marketable securities 1         1
Stock-based compensation 636   636      
Net loss $ (6,587)     (6,587)    
Ending balance (in shares) at Sep. 30, 2024 19,078,529 19,078,529        
Ending balance at Sep. 30, 2024 $ 38,126 $ 18 $ 126,339 $ (24,034) $ (64,000) $ (197)